Diagnostic Value of Serum a-L Fucose Gan Enzyme Combined with Serum Alpha-Fetoprotein for Primary Hepatic Carcinoma: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 HUOYi-shan ¹ ,  HUANGYan-chun ¹ , PENGYu-cheng ¹ , ZHANGXiao-guang ²

1. Laboratory Department, Tumor Hospital Affiliated of Xinjiang Medical University, Urumqi 830000, China;
2. Ultrasound Department, Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China;

Corresponding author：

HUANGYan-chun, Email: huangyanchun0619@sohu.com

Keywords：

a-L fucose gan enzyme; Alpha fetoprotein; Primary hepatocelluar carcinoma; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.20140215

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review serum a-L Fucose Gan Enzyme (AFU) combined with serum Alpha-Fetoprotein (AFP) in the diagnosis of primary hepatic carcinoma (PHC). Methods We comprehensively searched databases including PubMed, The Cochrane Library (Issue 2, 2013), WanFang Data, VIP, CBM, CNKI, EMbase, and Medalink for relevant studies on AFU combined with AFP in the diagnosis of PHC from inception to July 2013; meanwhile, manual search for the relevant Chinese journals were also performed. Two reviewers independently screened literature according to inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies. Then meta-analysis was performed using Meta-DiSc 1.4 software. Results A total of 20 studies involving 1 350 cases and 2 079 controls were included. The results of meta-analysis showed that, pooled sensitivity, specificity, positive likelihood radio, negative likelihood radio, diagnostic odds ratio, the area under SROC curve and Q index were:a) detection of AFU alone:0.76 (0.74, 0.78), 0.83 (0.82, 0.85), 7.09 (4.34, 11.58), 0.29 (0.23, 0.37), 26.88 (15.04, 48.06), 0.872 6 and 0.803, respectively; b) detection of AFP alone:0.69 (0.67, 0.72), 0.88 (0.86, 0.89), 7.85 (5.35, 11.50), 0.35 (0.30, 0.42), 25.62 (16.35, 40.15), 0.805 4 and 0.740 6, respectively; and c) combined detection of AFU and AFP:0.85 (0.83, 0.87), 0.86 (0.85, 0.88), 7.16 (5.15, 9.96), 0.15 (0.10, 0.23), 54.07 (29.85, 97.95), 0.940 8 and 0.878 5, respectively. Conclusion The combination detection of AFU and AFP has good efficacy in the diagnosis of PHC.

Citation： HUOYi-shan, HUANGYan-chun, PENGYu-cheng, ZHANGXiao-guang. Diagnostic Value of Serum a-L Fucose Gan Enzyme Combined with Serum Alpha-Fetoprotein for Primary Hepatic Carcinoma: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(11): 1326-1331. doi: 10.7507/1672-2531.20140215 Copy

1.	Saffroy R, Pham P, Reffs M, et al. New perspectives and strategy research biomarkers for hepatocellularcarcinoma. Clin Chem Lab Med, 2007, 45(9):1169-1179.
2.	赵睿, 王启之.肝癌诊断的肿瘤标志物研究进展.国际消化病杂志, 2013, 33(1):29-31.
3.	黄延平.电化学发光免疫分析(ECLIA)检测甲胎蛋白(AFP)对原发性肝癌的临床诊断价值.中国民康医学, 2010, 9(22):1127-1129.
4.	李小月, 李宗光, 沈继龙.血清a-L-岩藻糖苷酶和甲胎蛋白在原发性肝癌中的临床应用.安徽医学, 2011, 32(7):924-925.
5.	安哲, 李伟. AFP、AFU、GGT联合检测在原发性肝癌诊断中的应用.医药前沿, 2011, 1(16):31-32.
6.	沈剑平. AFP、AFU、GGT、ALP及CA19-9联合检测对肝癌的诊断价值.国际检验医学杂志, 2012, 33(10):1179-1180.
7.	Whiting P, Rutjes AW, Reitsma JB, 等. QUADAS的制定:用于系统评价中评价诊断性研究质量的工具.中国循证医学杂志, 2007, 7(4):296-306.
8.	周飞. 2项指标联合检测在诊断原发性肝癌中的应用.检验医学与临床, 2010, 7(21):2430-2431.
9.	陈建国, 高晓阳, 吴白平. 3项指标在原发性肝癌诊断治疗中的应用.检验医学与临床, 2012, 9(8):902-903.
10.	王洋, 余宪, 张旭, 等. AFP、AFU、GGT、ALP联合检测对原发性肝癌诊断价值的观察.实用肿瘤学杂志, 2012, 17(1):23-24.
11.	白吉明, 李建华, 钱浩, 等. AFP, AFU, GPC3, 联合检测在原发性肝癌诊断中的应用.河北医学, 2012, 18(4):496-498.
12.	于宏亮. AFP和AFU联合检测对肝脏疾病的临床应用价值探讨.中国实用医药, 2012, 7(10):123-124.
13.	Karamova ER, Yazova AK, Goussev AI, et al. Conformation varians of hunman alpha-fetoprotein. Tumor Biol, 1998, 19(4):310-317.
14.	谢远勤. AFU与AFP联合检测在诊断原发性肝癌中的应用.河北医学, 2011, 17(5):700-701.
15.	黄鑫刚, 史小波, 郭新荣. a-L-岩藻糖苷酶联合甲胎蛋白检测在原发性肝癌诊断中的临床评价.检验医学与临床, 2013, 9(7):779-780.
16.	周爱英, 丁乐顺.联合检测a-L-藻糖苷酶与甲胎蛋白对原发性肝癌的诊断价值.医学检验与临床, 2011, 22(1):42-43.
17.	叶波, 叶斌, 熊英.联合检测血清AFP和AFU对原发性肝癌的诊断价值.肿瘤预防与治疗, 2010, 23(3):234-235.
18.	徐焰, 陈名声, 郝小柯.联合检测血清AFU、AFP肿瘤标志物在原发性肝癌诊断中的临床价值.重庆医学, 2008, 37(24):2805-2806.
19.	徐天祥, 联合检测血清AFU和AFP对原发性肝癌的诊断价值.南京医科大学学报(自然科学版), 2008, 28(2):242-243.
20.	杜英, 徐彤, 刘翠晴, 等.浅谈血清AFU和AFP联合检测在早期原发性肝癌诊断中的应用.中国保健营养, 2013, 23(3):1543-1544.
21.	黄声旗, 熊利华.血清AFU、AFP和CAl9-9在原发性肝癌的诊断作用.放射免疫学杂志, 2012, 25(4):478-479.
22.	刘硕, 徐东强, 周秀英.血清AFU、AFP联合检测对原发性肝癌的诊断价值.现代保健·医学创新研究, 2008, 5(9):166.
23.	尹琍, 赵宗豪.血清AFU和AFP联合检测对原发性肝癌诊断的临床价值.安徽医学, 2010, 31(3):211-212.
24.	任文贵, 任怡, 刘彬, 等.血清AFU和AFP联合检测在原发性肝癌诊断中的应用.航空航天医学杂志, 2011, 22(4):442-443.
25.	吕婉娴, 叶铭坤.血清甲胎蛋白和a-L岩藻糖苷酶联合检测对原发性肝癌诊断的意义.实用医技杂志, 2011, 18(9):946-947.
26.	陈建军, 陈建国, 高晓阳, 等.应用ROC曲线评价AFP、AFU、5'-NT在原发性肝癌诊断中的意义.实用预防医学, 2012, 19(9):1402-1404.
27.	袁明生.应用受试者工作特征曲线评价甲胎蛋白、α-L岩藻糖苷酶、CA199及γ-谷氨酰转移酶检测对原发性肝癌的诊断价值.中国全科医学, 2011, 14(21):2372-2374.
28.	Dengnier Y, Le TA, Glaise D, at al. A study of lysosmal enzyme activities in serum and leukocytes in chronic hepatic disease. Clin Chim Acta, 1980, 108(3):385-392.
29.	俞吉芳, 雷文英, 崔风云. AFP、CAl99和AFU联合检测在原发性肝癌诊断中的应用.中华现代医学与临床, 2007, 6(3-4):58-59.
30.	杨克虎.系统评价指导手册.北京:人民卫生出版社, 2010:179-213.

1. Saffroy R, Pham P, Reffs M, et al. New perspectives and strategy research biomarkers for hepatocellularcarcinoma. Clin Chem Lab Med, 2007, 45(9):1169-1179.
2. 赵睿, 王启之.肝癌诊断的肿瘤标志物研究进展.国际消化病杂志, 2013, 33(1):29-31.
3. 黄延平.电化学发光免疫分析(ECLIA)检测甲胎蛋白(AFP)对原发性肝癌的临床诊断价值.中国民康医学, 2010, 9(22):1127-1129.
4. 李小月, 李宗光, 沈继龙.血清a-L-岩藻糖苷酶和甲胎蛋白在原发性肝癌中的临床应用.安徽医学, 2011, 32(7):924-925.
5. 安哲, 李伟. AFP、AFU、GGT联合检测在原发性肝癌诊断中的应用.医药前沿, 2011, 1(16):31-32.
6. 沈剑平. AFP、AFU、GGT、ALP及CA19-9联合检测对肝癌的诊断价值.国际检验医学杂志, 2012, 33(10):1179-1180.
7. Whiting P, Rutjes AW, Reitsma JB, 等. QUADAS的制定:用于系统评价中评价诊断性研究质量的工具.中国循证医学杂志, 2007, 7(4):296-306.
8. 周飞. 2项指标联合检测在诊断原发性肝癌中的应用.检验医学与临床, 2010, 7(21):2430-2431.
9. 陈建国, 高晓阳, 吴白平. 3项指标在原发性肝癌诊断治疗中的应用.检验医学与临床, 2012, 9(8):902-903.
10. 王洋, 余宪, 张旭, 等. AFP、AFU、GGT、ALP联合检测对原发性肝癌诊断价值的观察.实用肿瘤学杂志, 2012, 17(1):23-24.
11. 白吉明, 李建华, 钱浩, 等. AFP, AFU, GPC3, 联合检测在原发性肝癌诊断中的应用.河北医学, 2012, 18(4):496-498.
12. 于宏亮. AFP和AFU联合检测对肝脏疾病的临床应用价值探讨.中国实用医药, 2012, 7(10):123-124.
13. Karamova ER, Yazova AK, Goussev AI, et al. Conformation varians of hunman alpha-fetoprotein. Tumor Biol, 1998, 19(4):310-317.
14. 谢远勤. AFU与AFP联合检测在诊断原发性肝癌中的应用.河北医学, 2011, 17(5):700-701.
15. 黄鑫刚, 史小波, 郭新荣. a-L-岩藻糖苷酶联合甲胎蛋白检测在原发性肝癌诊断中的临床评价.检验医学与临床, 2013, 9(7):779-780.
16. 周爱英, 丁乐顺.联合检测a-L-藻糖苷酶与甲胎蛋白对原发性肝癌的诊断价值.医学检验与临床, 2011, 22(1):42-43.
17. 叶波, 叶斌, 熊英.联合检测血清AFP和AFU对原发性肝癌的诊断价值.肿瘤预防与治疗, 2010, 23(3):234-235.
18. 徐焰, 陈名声, 郝小柯.联合检测血清AFU、AFP肿瘤标志物在原发性肝癌诊断中的临床价值.重庆医学, 2008, 37(24):2805-2806.
19. 徐天祥, 联合检测血清AFU和AFP对原发性肝癌的诊断价值.南京医科大学学报(自然科学版), 2008, 28(2):242-243.
20. 杜英, 徐彤, 刘翠晴, 等.浅谈血清AFU和AFP联合检测在早期原发性肝癌诊断中的应用.中国保健营养, 2013, 23(3):1543-1544.
21. 黄声旗, 熊利华.血清AFU、AFP和CAl9-9在原发性肝癌的诊断作用.放射免疫学杂志, 2012, 25(4):478-479.
22. 刘硕, 徐东强, 周秀英.血清AFU、AFP联合检测对原发性肝癌的诊断价值.现代保健·医学创新研究, 2008, 5(9):166.
23. 尹琍, 赵宗豪.血清AFU和AFP联合检测对原发性肝癌诊断的临床价值.安徽医学, 2010, 31(3):211-212.
24. 任文贵, 任怡, 刘彬, 等.血清AFU和AFP联合检测在原发性肝癌诊断中的应用.航空航天医学杂志, 2011, 22(4):442-443.
25. 吕婉娴, 叶铭坤.血清甲胎蛋白和a-L岩藻糖苷酶联合检测对原发性肝癌诊断的意义.实用医技杂志, 2011, 18(9):946-947.
26. 陈建军, 陈建国, 高晓阳, 等.应用ROC曲线评价AFP、AFU、5'-NT在原发性肝癌诊断中的意义.实用预防医学, 2012, 19(9):1402-1404.
27. 袁明生.应用受试者工作特征曲线评价甲胎蛋白、α-L岩藻糖苷酶、CA199及γ-谷氨酰转移酶检测对原发性肝癌的诊断价值.中国全科医学, 2011, 14(21):2372-2374.
28. Dengnier Y, Le TA, Glaise D, at al. A study of lysosmal enzyme activities in serum and leukocytes in chronic hepatic disease. Clin Chim Acta, 1980, 108(3):385-392.
29. 俞吉芳, 雷文英, 崔风云. AFP、CAl99和AFU联合检测在原发性肝癌诊断中的应用.中华现代医学与临床, 2007, 6(3-4):58-59.
30. 杨克虎.系统评价指导手册.北京:人民卫生出版社, 2010:179-213.

Chinese Journal of Evidence-Based Medicine

Diagnostic Value of Serum a-L Fucose Gan Enzyme Combined with Serum Alpha-Fetoprotein for Primary Hepatic Carcinoma: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content